Royal Philips (NYSE:PHG) announced today that its Lumify with Reacts handheld tele-ultrasound imaging system is commercially available in Japan.
Japan’s healthcare authority cleared Lumify for compatible handheld devices in its healthcare market to make high-quality, portable ultrasound available almost everywhere in the country, according to a news release.
Lumify is designed for use in places where quick and easy access to diagnostic ultrasound imaging is required and is suitable for point-of-care use in hospitals, ambulances, doctor’s offices and patients’ homes during GP visits as well. It allows clinicians to remotely collaborate by sharing ultrasound images in real-time.
Amsterdam-based Philips also noted the value of Lumify as telehealth’s importance continues to grow amid the COVID-19 pandemic. Meanwhile, specific to Japan, which Philips said has a declining birthrate and aging population, the need for medical diagnostic equipment adaptable to changing demographics makes Lumify valuable in the market it is now entering.
“By bringing diagnostic insight to the point of care, Lumify is a great example of how Philips is supporting providers to deliver on the ambition of the ‘quadruple aim’ in healthcare: better health outcomes, an improved experience for patients and staff, and a lower cost of care,” Philips GM for access & obstetric ultrasound Matthijs Groot Wassink said in the release. “Its transducer connects to a smart device such as a tablet, making it a compact and highly durable solution. In addition, by utilizing Philips’ Lumify with Reacts capability, real-time ultrasound images can be shared between medical staff involved in collaboration during imaging procedures.”